Holen Sie sich die Stockscreener-App
11.00
0.90%
-0.10
Handel nachbörslich:
10.93
-0.07
-0.64%
Schlusskurs vom Vortag:
$11.10
Offen:
$11.16
24-Stunden-Volumen:
428.34K
Relative Volume:
1.83
Marktkapitalisierung:
$420.41M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
3.7162
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
+3.58%
1M Leistung:
+5.67%
6M Leistung:
+68.20%
1J Leistung:
-16.54%
1-Tages-Spanne:
$10.81
$11.56
1-Wochen-Bereich:
$10.63
$12.18
52-Wochen-Spanne:
$4.93
$14.27
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Vergleichen Sie TRDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
11.00 | 424.23M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Update Recap: Can Entrada Therapeutics Inc outperform under higher oil prices - baoquankhu1.vn
US Market Recap: How volatile is MOGB stockEarnings Summary Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Trading the Move, Not the Narrative: (TRDA) Edition - Stock Traders Daily
What insider trading reveals about Entrada Therapeutics Inc. stock2025 Momentum Check & AI Forecasted Stock Moves - bollywoodhelpline.com
Will Entrada Therapeutics Inc outperform the market in YEARTrade Volume Report & Fast Gain Stock Tips - baoquankhu1.vn
Signal Recap: Is Eastman Chemical Company stock a buy or sell2025 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
Quarterly Earnings: Can Onconetix Inc weather a recession2025 Winners & Losers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
(TRDA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Smart Money: Is Entrada Therapeutics Inc part of any major index2025 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 4.8%Should You Sell? - MarketBeat
Entrada updates progress in preclinical pipeline - BioWorld MedTech
Entrada Therapeutics reports progress across development portfolio - Yahoo Finance
Analyst Calls: Is Entrada Therapeutics Inc. stock safe for conservative investorsQuarterly Investment Review & AI Driven Stock Reports - Улправда
Is Entrada Therapeutics Inc. stock vulnerable to regulatory risks2025 Market Trends & Accurate Technical Buy Alerts - Улправда
Entrada Therapeutics Highlights Progress Across Its Portfolio of Rna-Based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - marketscreener.com
Entrada Therapeutics highlights RNA pipeline progress and outlook - TipRanks
Entrada reports progress on DMD treatments, shares clinical timeline By Investing.com - Investing.com Australia
Entrada Therapeutics Advances Clinical Pipeline and Reports Progress Amid Upcoming Data Releases and New Ocular Candidate Selection - Quiver Quantitative
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - The Manila Times
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewswire Inc.
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion - MSN
Price-Driven Insight from (TRDA) for Rule-Based Strategy - Stock Traders Daily
Azenta elects Entrada CEO to Board of Directors - MSN
Vesuvius India Limited Moves Into Overbought Range Analysts CautiousSell Signals and Alerts & Double Or Triple Wealth - bollywoodhelpline.com
Entrada Therapeutics Inc (TRDA) Stock News & Articles - 24/7 Wall St.
AVP Infracon Limited Breaks Below Key Support LevelGlobal Trade Effects & Affordable Trading Strategies - Bollywood Helpline
Analyst Downgrade: Will Entrada Therapeutics Inc stock return to pre crisis levels2025 Market Overview & Verified Entry Point Detection - Bộ Nội Vụ
Tubes Limited Inches Toward Key Resistance — Will It BreakRisk Adjusted Returns & Low Risk Trading Ideas - Bollywood Helpline
Beeyu Overseas Limited Included in Top Momentum ScanVolume Profile Analysis & Big Data Market Reports - Bollywood Helpline
Option Seller’s Risk Unlimited (in theory)REITs Market Trends & Big Gains Small Capital - bollywoodhelpline.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics Earnings Notes - Trefis
How Entrada Therapeutics Inc. stock compares to industry benchmarksDay Trade & Safe Capital Allocation Plans - Улправда
Is Entrada Therapeutics Inc. stock positioned for long term growth2025 Volume Leaders & Fast Momentum Stock Entry Tips - Улправда
Is Entrada Therapeutics Inc. stock safe for conservative investors2025 Big Picture & Verified Trade Idea Suggestions - Улправда
How Entrada Therapeutics Inc. stock reacts to job market dataWeekly Trade Review & Risk Controlled Swing Alerts - Улправда
How resilient is Entrada Therapeutics Inc. stock in market downturnsJuly 2025 Snapshot & Weekly High Return Stock Forecasts - DonanımHaber
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Will Entrada Therapeutics Inc. stock benefit from commodity pricesWeekly Trading Summary & Verified Technical Signals - DonanımHaber
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Entrada Therapeutics : Corporate Presentation December 2025 - marketscreener.com
5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA - MarketBeat
Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily
Entrada Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Reports Third Quarter 2025 Financial Results - ADVFN
Brokerages Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) Price Target at $20.67 - Defense World
Baker Bros. Advisors LP Increases Stake in Entrada Therapeutics Inc. - GuruFocus
Major Investment Alert: Baker Bros. Advisors Boosts Stake in Entrada Therapeutics! - TipRanks
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):